Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

Conclusions:
Alemtuzumab provides durable efficacy through 5 years in patients with an inadequate response to prior therapy in the absence of continuous treatment.

Classification of evidence:
This study provides Class III evidence that alemtuzumab provides efficacy and slowing of brain atrophy through 5 years.

Source: Neurology - September 11, 2017 Category: Neurology Authors: Coles, A. J., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H.-P., Havrdova, E., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., Margolin, D. H., Thangavelu, K., Chirieac, M. C., Jody, D., Xenopoulos, P., Hogan, R. J., Panzara, M. Tags: Autoimmune diseases, Clinical trials Randomized controlled (CONSORT agreement), Class III, Multiple sclerosis ARTICLE Source Type: research